SR One related stories
All articles and analysis
Macrolide Pharmaceuticals snags $20 mlnWatertown, Massachusetts-based Macrolide Pharmaceuticals, a developer of antibiotics for for drug-resistant, hospital-acquired infections, has raised $20 million in financing. The lead investors were Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Ventures and SR One.
- Pandion Therapeutics snags $58 mln Series A
Cambridge, Massachusetts-based Pandion Therapeutics, a biotech company, has closed $58 million in Series A financing. Polaris Partners, Versant Ventures and Roche Venture Fund led the round with participation from SR One and BioInnovation Capital.
- Palleon Pharmaceuticals attracts $47.6 mln Series A
Waltham, Massachusetts-based Palleon Pharmaceuticals, a developer of glycoimmune checkpoint inhibitors that treat cancer, has closed $47.6 million in Series A financing. The investors were SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures and AbbVie Ventures.
- ZappRx scores $25 mln Series B
Boston-based ZappRx Inc, a provider of a platform for electronic prescriptions, has raised $25 million in Series B funding. Qiming US Healthcare Fund led the round with participation from other investors that included SR One and GV. In addition to the funding, Mark McDade, a managing partner at Qiming US, has been appointed to ZappRx's board of directors.
- Pulmocide snags $30.4 mln Series B in SR One-led round
UK-based drug developer Pulmocide Ltd has closed $30.4 million in Series B financing. SR One led the round with participation from other investors that included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc.
- Goddard named non-executive Chairman of Mission Therapeutics
Mission Therapeutics said Dec. 5 that Dr Colin Goddard was named non-executive Chairman, effective January 1st 2017. Michael Moore, Mission's Founder Chairman, will continue on the board and transition to the role of Deputy Chairman. Mission Therapeutics, of Cambridge, England, is a drug discovery and development company.
- Morphic Therapeutic racks up $51.5 mln Series A
Waltham, Massachusetts-based Morphic Therapeutic, a biotechnology company focused on developing oral integrin drugs, has closed $51.5 million in Series A financing. SR One and Pfizer Venture Investments led the round with participation from other investors that included Omega Funds and AbbVie Ventures.
- Digital healthcare company Progyny snaps up $14.7 mln
New York City-based Progyny, a digital healthcare company, has raised $14.7 million in Series B funding. An unnamed family office led the round with participation from Kleiner Perkins Caufield and Byers, Mellon, SR One, TPG Biotech and Union Grove Venture Partners.